Home> Products> new medication regimen

{ "products": [ { "_id": "6a8c3838c90065ecdc86c757", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Semaglutide Injection 4mg", "description": "SAMIGLUTIDE 4 MG is a semaglutide-containing injectable medicine supplied in a pre-filled pen. The stated formulation contains 4 mg of semaglutide in 3 mL of solution, corresponding to approximately 1.34 mg/mL.\n\nSemaglutide is a GLP-1 receptor agonist that acts on physiological pathways involved in blood-glucose control, appetite, and gastrointestinal function. Its use should be based on the approved indication for the specific product and the advice of a qualified healthcare professional.\n\nProduct Overview\nProduct: SAMIGLUTIDE 4 MG\nActive substance: Semaglutide\nStrength: 4 mg/3 mL\nApproximate concentration: 1.34 mg/mL\nDosage form: Injectable solution\nPresentation: Pre-filled pen\nRoute: Subcutaneous administration, according to the applicable product instructions\n\nThe 4 mg/3 mL concentration is also associated with certain approved semaglutide products. However, this does not mean that their dosing schedules, indications, or administration instructions automatically apply to SAMIGLUTIDE 4 MG. The product-specific labeling should always be followed.\n\nWhat Is Semaglutide?\n\nSemaglutide is a medication belonging to the GLP-1 receptor agonist class. It acts similarly to the naturally occurring hormone glucagon-like peptide-1 (GLP-1).\n\nGLP-1 is involved in several processes related to metabolism. Its activity can influence insulin secretion, glucagon regulation, stomach emptying, and appetite. Depending on the particular semaglutide product and its regulatory authorization, semaglutide may be prescribed for conditions such as type 2 diabetes or chronic weight management in appropriately selected patients.\n\nBecause different semaglutide products can have different approved uses and formulations, treatment decisions should be based on the specific medicine being prescribed.\n\nSAMIGLUTIDE 4 MG Pre-Filled Pen\n\nSAMIGLUTIDE 4 MG is supplied in a pre-filled pen intended to provide a convenient format for subcutaneous administration.\n\nPre-filled devices can eliminate the need to draw medication from a conventional vial. Nevertheless, patients should be properly trained before using an injectable pen and should follow the instructions supplied with the specific product.\n\nThe pen should only be used according to its approved instructions, including the prescribed dose and administration schedule.\n\nStrength and Formulation\n\nEach stated 3 mL presentation contains 4 mg of semaglutide, giving a concentration of approximately 1.34 mg/mL.\n\nThe concentration of a medicine should not be confused with the amount delivered in every injection. The quantity administered depends on the design and dose settings of the particular pen.\n\nFor this reason, patients should not calculate or select their own dose based solely on the concentration printed on the package. The prescribed dose should come from the product's authorized instructions and the treating healthcare professional.\n\nHow Semaglutide Acts\n\nSemaglutide activates GLP-1 receptors, which are involved in the regulation of blood glucose and appetite.\n\nAmong its physiological effects, GLP-1 receptor activation can:\n\nSupport glucose-dependent insulin secretion.\nReduce inappropriate glucagon secretion when blood glucose is elevated.\nAffect gastrointestinal activity, including gastric emptying.\nInfluence appetite and food intake.\n\nThe overall response to treatment can vary between individuals and depends on factors such as the medical indication, prescribed dose, treatment duration, and other medicines being used.\n\nPotential Therapeutic Benefits\n\nWhen prescribed for an appropriate, authorized indication, semaglutide may form part of a broader treatment program.\n\nFor eligible individuals with type 2 diabetes, certain approved semaglutide medicines are used to improve glycemic control. Other approved semaglutide formulations have indications involving chronic weight management for qualifying patients.\n\nMedication should be considered alongside the broader treatment strategy recommended by a healthcare professional, which may include nutritional management, physical activity, glucose monitoring, and other appropriate interventions.\n\nPossible Side Effects\n\nLike other prescription medicines, semaglutide can cause unwanted effects.\n\nFrequently reported gastrointestinal reactions associated with semaglutide products include:\n\nNausea\nVomiting\nDiarrhea\nConstipation\nAbdominal discomfort or pain\n\nNot every patient experiences these effects, and their severity can vary.\n\nSemaglutide products also have important safety considerations. Depending on the specific approved product, labeling includes warnings concerning conditions such as pancreatitis, gallbladder-related problems, severe gastrointestinal reactions, kidney problems associated with dehydration, and serious hypersensitivity reactions.\n\nPatients should provide their healthcare professional with a complete medical history before treatment begins.\n\nImportant Contraindications and Warnings\n\nCertain semaglutide products carry a contraindication for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious hypersensitivity to semaglutide or an applicable component is also an important contraindication.\n\nThe exact warnings and contraindications applicable to SAMIGLUTIDE 4 MG should be confirmed against its current authorized product information in the relevant country.\n\nPatients should seek professional medical advice if they develop concerning symptoms during treatment.\n\nCorrect Administration\n\nSAMIGLUTIDE 4 MG should be administered only according to the prescription and instructions applicable to the product.\n\nBefore using a pre-filled pen, patients should receive appropriate instruction regarding:\n\nDose selection\nInjection technique\nInjection sites\nPen operation\nStorage\nDisposal of used needles or injection equipment\n\nThe dose or frequency should never be changed independently.\n\nA pre-filled injection pen should not be shared with another person, even if a new needle is attached. Sharing injectable medication devices can create a risk of transmitting infections and is contrary to appropriate safe-use practices.\n\nStorage\n\nStorage requirements should be determined from the official SAMIGLUTIDE 4 MG packaging and product information supplied with the medicine.\n\nPatients should not rely on storage instructions from a different semaglutide brand because formulations, devices, and stability requirements can differ between products.\n\nUse by Healthcare Professionals\n\nHealthcare professionals should assess whether SAMIGLUTIDE 4 MG is appropriate for an individual patient by considering the relevant diagnosis, treatment objectives, medical history, contraindications, concurrent medicines, and applicable regulatory requirements.\n\nParticular attention should be given to the distinction between different semaglutide products. Although they contain the same active ingredient, products may differ in:\n\nApproved indications\nConcentration\nPen design\nDose increments\nAdministration schedules\nStorage conditions\nRegulatory labeling\n\nThe product-specific prescribing information should therefore be consulted before treatment is initiated or adjusted.\n\nAdvantages of a Pre-Filled Pen\n\nA pre-filled pen can provide a practical method of administering an injectable medicine. Compared with a conventional vial-and-syringe presentation, the device may reduce some preparation steps and can be convenient for patients who have been appropriately trained.\n\nConvenience, however, should not take precedence over product authenticity, regulatory approval, correct dosing, proper storage, and professional medical supervision.\n\nSAMIGLUTIDE 4 MG: Key Points\n\nSAMIGLUTIDE 4 MG is described as a semaglutide injection containing 4 mg in 3 mL, supplied in a pre-filled pen.\n\nThe most important considerations are:\n\nSemaglutide is a GLP-1 receptor agonist.\nThe stated formulation is 4 mg/3 mL (approximately 1.34 mg/mL).\nAdministration is by the subcutaneous route when prescribed for that route.\nThe appropriate dose and frequency must come from the product-specific instructions and prescription.\nDosing information from another semaglutide brand should not automatically be applied.\nPatients should be informed about possible adverse reactions and relevant contraindications.\nThe pen must not be shared between patients.\nStorage and handling should follow the official product information.\nTreatment should be supervised by an appropriately qualified healthcare professional.\nFrequently Asked Questions\nWhat is SAMIGLUTIDE 4 MG?\n\nSAMIGLUTIDE 4 MG is a semaglutide-containing injectable formulation described as 4 mg/3 mL, supplied in a pre-filled pen. Its approved use depends on the regulatory authorization applicable to the product and market.\n\nWhat does 4 mg/3 mL mean?\n\nIt indicates that the stated 3 mL presentation contains a total of 4 mg of semaglutide, equivalent to approximately 1.34 mg of semaglutide per mL.\n\nThis concentration alone should not be used to determine an individual's injection dose.\n\nIs SAMIGLUTIDE 4 MG a prescription medicine?\n\nSemaglutide medicines are prescription products in many jurisdictions. SAMIGLUTIDE 4 MG should be used only in accordance with applicable regulations, authorized product information, and professional medical advice.\n\nHow is SAMIGLUTIDE 4 MG administered?\n\nThe product is described as a subcutaneous injection. However, the exact dose, injection frequency, and pen operation should be determined from the SAMIGLUTIDE 4 MG product information and the patient's prescription.\n\nCan SAMIGLUTIDE 4 MG be taken together with another semaglutide medicine?\n\nPatients should not combine semaglutide-containing medicines or switch between them without medical supervision. Some approved semaglutide labels specifically advise against combining their product with another semaglutide-containing medicine or another GLP-1 receptor agonist.\n\nCan the dose be changed without consulting a doctor?\n\nNo. Patients should not increase, decrease, or otherwise modify the prescribed dose or injection schedule without guidance from their healthcare professional.\n\nConclusion\n\nSAMIGLUTIDE 4 MG – Semaglutide Injection 4 mg/3 mL (approximately 1.34 mg/mL) Pre-Filled Pen is a semaglutide-based injectable formulation designed for subcutaneous use according to its applicable product instructions.\n\nBecause semaglutide products can vary substantially in their approved indications, concentrations, devices, and dosing regimens, information from another semaglutide product should not be assumed to apply to SAMIGLUTIDE 4 MG.\n\nFor appropriate and safe use, patients and healthcare professionals should rely on the current official product information, local regulatory authorization, and individualized medical advice. Any questions concerning suitability, dosing, interactions, contraindications, or adverse effects should be discussed with a qualified healthcare professional.", "price": 6600.0, "discountamount": 1980.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2497, "imageuri": "https://productimages.withfloats.com/actual/6a8c383c0e00e8a5dab0c9d5.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a8c383c0e00e8a5dab0c9d5.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-08-24T12:25:28.659Z", "updatedon": "2026-08-24T12:25:28.659Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/semaglutide-injection-4mg/2497", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SAMIGLUTIDE 4 MG", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6a2937c45f38850c17a50eea", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "minoxidil topical solution usp 2%", "description": "Introduction to Minoxidil Topical Solution USP 2%\n\nMinoxidil Topical Solution USP 2% is a clinically proven hair regrowth treatment widely used for managing hair thinning and hair loss in both men and women. Originally developed as a medication for high blood pressure, researchers discovered that Minoxidil had a remarkable ability to stimulate hair growth and improve hair density. Today, it is one of the most trusted and dermatologist-recommended treatments for androgenetic alopecia (pattern baldness) and other forms of hair loss.\n\nHair loss can significantly affect self-confidence and quality of life. Whether caused by genetics, hormonal changes, stress, aging, or medical conditions, thinning hair can be frustrating. Minoxidil Topical Solution USP 2% offers a scientifically backed solution designed to revitalize hair follicles, improve scalp circulation, and promote healthier, thicker hair growth.\n\nThis comprehensive guide explains everything you need to know about Minoxidil Topical Solution USP 2%, including its uses, benefits, mechanism of action, side effects, application methods, and frequently asked questions.\n\nWhat Is Minoxidil Topical Solution USP 2%?\n\nMinoxidil Topical Solution USP 2% is an external-use medication applied directly to the scalp to promote hair regrowth and slow down progressive hair loss. It contains 2% Minoxidil as the active ingredient and is formulated specifically to stimulate hair follicles and encourage healthy hair growth.\n\nThis topical treatment is commonly prescribed or recommended for individuals experiencing:\n\nMale pattern baldness\nFemale pattern hair loss\nHair thinning\nEarly-stage alopecia\nReduced hair density\n\nThe 2% strength is often preferred for women and individuals seeking a milder concentration while still benefiting from effective hair growth stimulation.\n\nComposition of Minoxidil Topical Solution USP 2%\nActive Ingredient\nMinoxidil USP 2% w/v\n\nMinoxidil is a vasodilator that improves blood flow to hair follicles and helps extend the hair growth cycle.\n\nOther Ingredients\n\nDepending on the manufacturer, the formulation may also contain:\n\nPurified Water\nEthanol\nPropylene Glycol\nStabilizing agents\nPreservatives\n\nThese ingredients help ensure proper absorption and effectiveness of the solution.\n\nHow Does Minoxidil Topical Solution USP 2% Work?\n\nMinoxidil works by revitalizing shrinking hair follicles and prolonging the growth phase of the hair cycle.\n\nHair Growth Cycle Overview\n\nHair grows in three main stages:\n\n1. Anagen Phase (Growth Phase)\n\nThe active growth stage where hair follicles produce new hair strands.\n\n2. Catagen Phase (Transition Phase)\n\nA brief period where hair growth slows.\n\n3. Telogen Phase (Resting Phase)\n\nHair eventually sheds and makes way for new growth.\n\nIn people experiencing pattern hair loss, the anagen phase becomes shorter, and hair follicles gradually shrink.\n\nMechanism of Action of Minoxidil\n\nMinoxidil Topical Solution USP 2% works by:\n\nIncreasing Blood Circulation\n\nMinoxidil improves blood flow around hair follicles, ensuring better delivery of oxygen and nutrients.\n\nStimulating Dormant Hair Follicles\n\nIt helps reactivate weakened follicles that have stopped producing healthy hair.\n\nExtending the Growth Phase\n\nMinoxidil prolongs the anagen phase, allowing hair to grow thicker and longer.\n\nEnhancing Follicular Function\n\nHair follicles become healthier and more productive over time.\n\nIncreasing Hair Density\n\nRegular application can improve scalp coverage and hair volume.\n\nUses of Minoxidil Topical Solution USP 2%\n1. Treatment of Androgenetic Alopecia\n\nThe primary use of Minoxidil Topical Solution USP 2% is managing hereditary hair loss in both men and women.\n\nBenefits include:\nReduced hair thinning\nImproved hair density\nEnhanced scalp coverage\nSlowed progression of baldness\n2. Female Pattern Hair Loss\n\nMinoxidil 2% is commonly recommended for women experiencing:\n\nDiffuse hair thinning\nWidening hair part\nReduced hair volume\n\nMany dermatologists consider 2% Minoxidil a first-line treatment option for female hair loss.\n\n3. Early Hair Loss Management\n\nIndividuals noticing initial signs of hair thinning may benefit from early treatment to preserve existing hair.\n\n4. Hair Follicle Revitalization\n\nMinoxidil helps improve the condition of miniaturized follicles, encouraging healthier growth patterns.\n\n5. Hair Density Enhancement\n\nRegular use may result in fuller, thicker-looking hair over time.\n\nKey Benefits of Minoxidil Topical Solution USP 2%\nClinically Proven Hair Regrowth\n\nMinoxidil is one of the most extensively studied and scientifically validated hair growth treatments available today.\n\nNon-Invasive Treatment\n\nUnlike hair transplantation procedures, Minoxidil provides a non-surgical approach to hair restoration.\n\nImproved Hair Thickness\n\nMany users experience:\n\nThicker hair strands\nIncreased hair volume\nBetter scalp coverage\nSlows Progressive Hair Loss\n\nMinoxidil helps slow the natural progression of androgenetic alopecia.\n\nEasy to Apply\n\nThe topical solution can be applied directly to affected scalp areas using a dropper or applicator.\n\nSuitable for Long-Term Use\n\nWith proper medical guidance, Minoxidil can be safely used as part of a long-term hair care regimen.\n\nSupports Hair Follicle Health\n\nImproved blood circulation contributes to healthier follicular activity and stronger hair growth.\n\nBoosts Confidence and Appearance\n\nSuccessful hair regrowth can positively impact:\n\nSelf-esteem\nPersonal appearance\nSocial confidence\nPsychological well-being\nWho Can Use Minoxidil Topical Solution USP 2%?\n\nMinoxidil 2% may be suitable for:\n\nAdult men experiencing early-stage hair loss\nWomen with diffuse hair thinning\nIndividuals with hereditary hair loss\nPatients seeking non-surgical hair restoration options\nPeople looking to improve hair density\n\nA healthcare professional or dermatologist should determine whether this treatment is appropriate for your specific condition.\n\nHow to Apply Minoxidil Topical Solution USP 2%\n\nFor optimal results:\n\nStep 1\n\nEnsure the scalp is clean and completely dry.\n\nStep 2\n\nApply the recommended amount directly to the affected scalp area.\n\nStep 3\n\nGently spread the solution using fingertips if instructed.\n\nStep 4\n\nAllow the solution to dry naturally.\n\nStep 5\n\nWash hands thoroughly after application.\n\nStep 6\n\nUse consistently as directed by your healthcare provider.\n\nRegular application is essential for achieving the best outcomes.\n\nWhen Can Results Be Expected?\n\nHair regrowth is a gradual process.\n\nTypical Timeline\nFirst 1–2 Months\n\nSome users may notice temporary shedding as older hairs are replaced.\n\n3–4 Months\n\nInitial improvements in hair growth may become visible.\n\n4–6 Months\n\nHair density and scalp coverage may continue to improve.\n\n6–12 Months\n\nMaximum benefits are often observed with consistent long-term use.\n\nResults vary from person to person depending on age, genetics, and the severity of hair loss.\n\nWhy Choose Minoxidil Topical Solution USP 2%?\nTrusted Worldwide\n\nMinoxidil remains one of the most recommended hair regrowth treatments globally.\n\nProven Effectiveness\n\nNumerous clinical studies support its ability to promote hair growth and reduce hair loss.\n\nEasy Integration into Daily Routine\n\nApplication requires minimal time and effort.\n\nCost-Effective Hair Loss Solution\n\nCompared to surgical hair restoration procedures, Minoxidil offers an affordable alternative.\n\nSuitable for Men and Women\n\nThe 2% formulation is particularly popular among female users while also benefiting many men with mild to moderate hair loss.\n\nPossible Side Effects of Minoxidil Topical Solution USP 2%\n\nLike any medication, Minoxidil may cause side effects in some individuals.\n\nCommon Side Effects\nScalp Irritation\n\nSome users may experience:\n\nRedness\nItching\nDryness\nMild burning sensation\nFlaking or Scaling\n\nThe scalp may become slightly dry during treatment.\n\nTemporary Hair Shedding\n\nAn increase in hair shedding may occur during the initial weeks of treatment.\n\nThis is often a normal sign that older hairs are being replaced by new growth.\n\nLess Common Side Effects\nHeadache\n\nA small percentage of users may experience mild headaches.\n\nDizziness\n\nRarely, some individuals may feel lightheaded.\n\nUnwanted Hair Growth\n\nHair growth may occur in unintended areas if the solution comes into contact with other parts of the body.\n\nSerious Side Effects Requiring Medical Attention\n\nSeek immediate medical assistance if you experience:\n\nChest pain\nRapid heartbeat\nSevere dizziness\nSwelling of hands or feet\nDifficulty breathing\nSevere allergic reactions\n\nAlthough uncommon, these reactions require prompt evaluation.\n\nPrecautions and Warnings\nFor External Use Only\n\nMinoxidil Topical Solution USP 2% should only be applied to the scalp.\n\nAvoid Contact with Eyes\n\nIf accidental contact occurs, rinse thoroughly with water.\n\nDo Not Apply to Damaged Skin\n\nAvoid use on irritated, infected, or injured scalp areas.\n\nPregnancy and Breastfeeding\n\nConsult a healthcare provider before use during pregnancy or breastfeeding.\n\nKeep Away from Children\n\nStore safely and securely out of reach of children.\n\nStorage Instructions\n\nTo maintain product quality:\n\nStore in a cool, dry place.\nKeep away from direct sunlight.\nClose the container tightly after use.\nProtect from excessive heat and moisture.\nFrequently Asked Questions (FAQs)\nWhat is Minoxidil Topical Solution USP 2% used for?\n\nIt is used to treat hair loss and promote hair regrowth in individuals with androgenetic alopecia and hair thinning.\n\nIs Minoxidil 2% effective for women?\n\nYes. Minoxidil 2% is commonly recommended for female pattern hair loss.\n\nHow long should I use Minoxidil?\n\nHair growth maintenance generally requires continued use as directed by a healthcare professional.\n\nCan Minoxidil cure baldness permanently?\n\nNo. It helps manage hair loss and stimulate regrowth but does not permanently cure hereditary baldness.\n\nCan I use hair products while using Minoxidil?\n\nMost hair care products can be used, but it is advisable to apply them after the solution has completely dried.\n\nConclusion\n\nMinoxidil Topical Solution USP 2% is a trusted, clinically proven, and widely recommended treatment for hair loss and hair thinning. By improving blood circulation to hair follicles, extending the hair growth cycle, and stimulating dormant follicles, it helps promote healthier, thicker, and fuller hair growth over time.", "price": 395.0, "discountamount": 119.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2451, "imageuri": "https://productimages.withfloats.com/actual/6a2937c6210ffc3626055f86.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a2937c6210ffc3626055f86.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-06-10T10:09:08.796Z", "updatedon": "2026-06-10T10:09:08.796Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//minoxidil-topical-solution-usp-2-/2451", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "MINOXIHAIR 2%", "category": "DERMATALOGY", "tags": [ "minoxidil topical solution usp 2%", "minoxidil topical solution usp 2 %", "minoxidil topical solution usp 2% w/v" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "698eccba9206f8f071919fc7", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "clobetasol neomycin miconazole cream", "description": "EUROSOFT 4D CREAM represents a sophisticated breakthrough in topical dermatological therapy, combining three powerful active ingredients—clobetasol propionate, neomycin sulfate, and miconazole nitrate—into one comprehensive treatment formulation. This advanced pharmaceutical preparation is specifically designed to address complex skin conditions that involve inflammation, bacterial infection, and fungal colonization simultaneously. The “4D” designation reflects the cream's multidimensional approach to skin healing: it reduces inflammation, eliminates bacterial pathogens, eradicates fungal infections, and promotes overall skin restoration.This prescription-strength cream has been formulated using advanced pharmaceutical technology to ensure optimal penetration, stability, and efficacy. Each gram of EUROSOFT 4D CREAM delivers precise therapeutic doses of its active components, working synergistically to provide rapid relief and comprehensive healing for challenging dermatological conditions that might otherwise require multiple separate medications.Comprehensive Uses and ApplicationsEUROSOFT 4D CREAM is prescribed for a diverse range of dermatological conditions where multiple pathogenic factors contribute to skin disease. The primary indications include infected eczema, where both inflammation and secondary bacterial or fungal infection complicate the condition. Patients suffering from seborrheic dermatitis with secondary infection find significant relief with this triple-action formulation, as it addresses both the inflammatory component and the microbial colonization that often perpetuates this chronic condition.The cream proves particularly valuable in treating intertrigo—inflammatory conditions occurring in skin folds—where moisture, friction, and warmth create an ideal environment for both bacterial and fungal proliferation alongside inflammatory responses. Athletes dealing with infected dermatoses, including cases where fungal infections like tinea have become complicated by bacterial superinfection, benefit from the comprehensive coverage this medication provides.Contact dermatitis cases that have developed secondary infections respond well to EUROSOFT 4D CREAM, as the corticosteroid component addresses the allergic or irritant inflammatory response while the antimicrobial agents tackle opportunistic infections. The cream is also employed in managing various forms of infected psoriasis, particularly in intertriginous areas where both inflammation and infection coexist, creating a challenging therapeutic scenario.Medical professionals may prescribe this formulation for other complex dermatological conditions where the simultaneous presence of inflammation, bacterial infection, and fungal colonization requires a multifaceted treatment approach. The convenience of a single application containing all three therapeutic agents significantly improves patient compliance compared to using multiple separate medications.Key Benefits and Therapeutic AdvantagesThe primary advantage of EUROSOFT 4D CREAM lies in its comprehensive, multi-targeted action. The clobetasol propionate component is a super-potent corticosteroid that rapidly suppresses inflammation, reducing redness, swelling, itching, and discomfort. This powerful anti-inflammatory effect provides quick symptomatic relief, often noticeable within the first few applications, dramatically improving patient comfort and quality of life.Neomycin sulfate, a broad-spectrum aminoglycoside antibiotic, effectively eliminates a wide range of gram-positive and gram-negative bacteria commonly responsible for secondary skin infections. By controlling bacterial proliferation, it prevents infection from spreading, reduces the risk of complications, and accelerates the healing process. This antibacterial protection is crucial in preventing the vicious cycle where infection perpetuates inflammation and vice versa.The miconazole nitrate component provides robust antifungal coverage against dermatophytes, yeasts, and other pathogenic fungi that frequently complicate inflammatory skin conditions. Its fungicidal action ensures complete eradication of fungal elements, preventing recurrence and breaking the cycle of persistent infection that can undermine other therapeutic efforts.The synergistic formulation means patients need only one medication rather than juggling multiple creams or ointments, significantly simplifying their treatment regimen. This convenience improves adherence to prescribed therapy, leading to better outcomes. The cream base is designed for optimal absorption and comfortable application, avoiding the greasiness or stickiness that might deter regular use.EUROSOFT 4D CREAM typically produces visible improvements within days, though complete resolution requires completing the full prescribed course. The rapid symptom relief—particularly reduction in itching, pain, and visible inflammation—provides significant psychological and physical comfort to patients struggling with distressing skin conditions. By addressing all three pathological factors simultaneously, the cream prevents the common problem of treating one aspect of the condition while another remains unaddressed and continues causing symptoms.Important Side Effects and PrecautionsWhile EUROSOFT 4D CREAM is highly effective, users should be aware of potential side effects associated with its potent active ingredients. The clobetasol component, being a super-potent corticosteroid, can cause skin thinning (atrophy), stretch marks (striae), telangiectasia (visible blood vessels), and changes in skin pigmentation with prolonged use. These effects are more likely when the cream is used on thin-skinned areas like the face, groin, or underarms, or when applied under occlusive dressings.Systemic absorption of clobetasol, particularly with extensive application or prolonged use, may suppress the hypothalamic-pituitary-adrenal (HPA) axis, potentially affecting the body's natural cortisol production. This is especially concerning in children, whose body surface area to weight ratio makes them more vulnerable to systemic effects. Other corticosteroid-related effects may include acne-like eruptions, perioral dermatitis, delayed wound healing, and increased susceptibility to skin infections if protective immunity is compromised.Neomycin can cause contact sensitization in susceptible individuals, leading to allergic contact dermatitis. This manifests as increased redness, itching, or rash that paradoxically worsens with continued use. Cross-sensitivity with other aminoglycoside antibiotics is possible. Though rare with topical application, systemic absorption of neomycin could theoretically cause ototoxicity or nephrotoxicity, particularly if applied to large surface areas or compromised skin.Miconazole is generally well-tolerated but can occasionally cause local irritation, burning, or allergic reactions. Some users report mild stinging upon initial application, which typically subsides with continued use.Users should avoid applying the cream to the face for extended periods, near the eyes, or on broken skin unless specifically directed by their healthcare provider. The medication should not be used during pregnancy or breastfeeding without medical supervision. Parents should exercise particular caution when using this cream on children, as pediatric patients are more susceptible to systemic corticosteroid effects.If symptoms worsen, if new symptoms develop, or if no improvement occurs after one week of use, patients should consult their healthcare provider promptly. Signs of possible adverse reactions include excessive irritation, severe itching, rash expansion, or signs of spreading infection.ConclusionEUROSOFT 4D CREAM represents an innovative and highly effective solution for complex dermatological conditions requiring simultaneous anti-inflammatory, antibacterial, and antifungal therapy. Its triple-action formulation addresses the multifaceted nature of infected inflammatory skin diseases, providing comprehensive treatment in a single convenient application. The synergistic combination of clobetasol propionate, neomycin sulfate, and miconazole nitrate delivers rapid symptom relief while promoting complete healing.", "price": 91.0, "discountamount": 27.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2302, "imageuri": "https://productimages.withfloats.com/actual/698eccbd3d2f9770ce0bdd1c.png", "tileimageuri": "https://productimages.withfloats.com/tile/698eccbd3d2f9770ce0bdd1c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-02-13T07:03:22.253Z", "updatedon": "2026-03-12T08:14:48.969Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//clobetasol-neomycin-miconazole-cream/2302", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "EUROSOFT 4D CREAM", "category": "DERMATALOGY", "tags": [ "Clobetasol Neomycin Miconazole cream", "Clobetasol combination antifungal cream", "Clobetasol Neomycin Miconazole Chlorhexidine cream", "Triple action steroid antibiotic antifungal cream", "Miconazole Neomycin steroid skin cream", "Clobetasol Neomycin antifungal cream 0.5%" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694d14f6274fc8b97e9b7120", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Mirtazapine 30mg", "description": "MIRTAZPRIME 30 is a pharmaceutical formulation containing Mirtazapine 30mg as per Indian Pharmacopoeia (IP) standards. This prescription medication belongs to a class of drugs known as tetracyclic antidepressants and represents an advanced therapeutic option for individuals struggling with major depressive disorder and related mental health conditions. Manufactured under stringent quality control measures, MIRTAZPRIME 30 offers patients a reliable and effective solution for managing depression while also addressing associated symptoms such as insomnia and anxiety.\nMirtazapine, the active pharmaceutical ingredient in MIRTAZPRIME 30, works through a unique dual mechanism that distinguishes it from other antidepressants. Unlike selective serotonin reuptake inhibitors (SSRIs), mirtazapine enhances the release of both norepinephrine and serotonin in the brain by blocking specific receptors. This innovative approach not only helps alleviate depressive symptoms but also provides sedative effects that can be particularly beneficial for patients experiencing sleep disturbances alongside depression.\nTherapeutic Uses and Applications\nMIRTAZPRIME 30 is primarily indicated for the treatment of major depressive disorder (MDD), a serious mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in daily activities. The medication has demonstrated significant efficacy in clinical trials, showing improvement in mood, energy levels, and overall quality of life for patients suffering from depression.\nBeyond its primary indication, healthcare providers may prescribe MIRTAZPRIME 30 for various off-label uses based on clinical judgment and patient needs. The medication has shown promise in managing generalized anxiety disorder, where excessive worry and tension interfere with daily functioning. Its sedative properties make it particularly valuable for patients experiencing insomnia related to depression or anxiety, as it can help restore healthy sleep patterns without the need for additional sleep medications.\nThe 30mg dosage strength represents a therapeutic level commonly prescribed for maintenance treatment after initial dose titration. Patients typically begin with lower doses and gradually increase to 30mg as their body adjusts to the medication and their symptoms require more robust management. This dosage provides an optimal balance between therapeutic efficacy and side effect management for many individuals.\nMIRTAZPRIME 30 may also be considered for patients who have not responded adequately to other antidepressant therapies, offering an alternative mechanism of action that can break through treatment-resistant depression. Additionally, its appetite-stimulating effects can be beneficial for patients experiencing significant weight loss due to depression or other medical conditions.\nKey Benefits and Therapeutic Advantages\nThe benefits of MIRTAZPRIME 30 extend beyond simple symptom relief, offering patients a multifaceted approach to mental health recovery. One of the most significant advantages is its relatively rapid onset of action compared to many other antidepressants. While most SSRIs require several weeks to demonstrate meaningful clinical improvement, patients taking mirtazapine often experience some relief from symptoms within one to two weeks, with continued improvement over subsequent weeks.\nThe dual neurotransmitter action of MIRTAZPRIME 30 provides comprehensive coverage of depressive symptoms. By enhancing both serotonergic and noradrenergic neurotransmission, the medication addresses the complex neurochemical imbalances underlying depression more thoroughly than single-mechanism antidepressants. This broader action can result in more complete symptom resolution and better overall outcomes.\nSleep improvement represents another crucial benefit of MIRTAZPRIME 30. The medication's sedative properties, particularly pronounced at lower doses, help patients fall asleep faster and enjoy more restorative sleep throughout the night. This is especially valuable since sleep disturbances are both a symptom and an exacerbating factor in depression. Better sleep quality contributes to improved daytime functioning, energy levels, and emotional regulation.\nUnlike many antidepressants that commonly cause sexual dysfunction, MIRTAZPRIME 30 has a relatively favorable profile in this regard. The medication is less likely to interfere with sexual function, making it an attractive option for patients who have experienced these troublesome side effects with other antidepressants. This characteristic can significantly improve treatment adherence and quality of life.\nThe appetite-stimulating effect, while considered a side effect by some, can be therapeutically beneficial for patients experiencing significant weight loss or poor appetite due to depression. MIRTAZPRIME 30 can help restore healthy eating patterns and reverse the physical decline that often accompanies severe depressive episodes.\nFurthermore, MIRTAZPRIME 30 does not typically cause the gastrointestinal side effects commonly associated with SSRI antidepressants, such as nausea, diarrhea, or stomach upset. This improved gastrointestinal tolerability enhances patient comfort and compliance with treatment regimens.\nPotential Side Effects and Safety Considerations\nWhile MIRTAZPRIME 30 offers numerous therapeutic benefits, patients should be aware of potential side effects that may occur during treatment. Understanding these effects helps patients make informed decisions and enables early identification of any concerning symptoms requiring medical attention.\nThe most commonly reported side effect is drowsiness or sedation, particularly during the initial weeks of treatment. This effect is typically most pronounced during the first few hours after taking the medication, which is why it's generally recommended for evening administration. Patients should exercise caution when driving, operating machinery, or engaging in activities requiring alertness until they understand how the medication affects them personally.\nIncreased appetite and weight gain represent another frequent side effect of MIRTAZPRIME 30. While beneficial for some patients, others may find this effect undesirable. Weight gain typically ranges from moderate to significant and appears to be dose-related. Patients concerned about weight should discuss dietary strategies and exercise plans with their healthcare provider.\nDry mouth is a common anticholinergic side effect that can cause discomfort but is generally manageable through increased fluid intake, sugar-free gum or candy, and good oral hygiene practices. Some patients may also experience dizziness, particularly when standing up quickly, due to the medication's effects on blood pressure regulation.\nConstipation may occur in some patients and can usually be managed through dietary modifications, increased fiber intake, adequate hydration, and regular physical activity. Less commonly, patients might experience confusion, abnormal dreams, or changes in thinking, particularly in older adults who may be more sensitive to the medication's effects.\nSerious side effects, while rare, require immediate medical attention. These include signs of allergic reactions such as rash, itching, swelling, severe dizziness, or difficulty breathing. Agranulocytosis, a dangerous decrease in white blood cells, is an extremely rare but serious complication that manifests as fever, sore throat, or signs of infection. Any unexplained fever or signs of infection should prompt immediate contact with a healthcare provider.\nSerotonin syndrome is another rare but potentially life-threatening condition that can occur when mirtazapine is combined with other medications affecting serotonin levels. Symptoms include agitation, hallucinations, rapid heartbeat, fever, excessive sweating, muscle stiffness, or coordination problems. Patients should inform their healthcare provider about all medications and supplements they are taking to avoid dangerous interactions.\nAbrupt discontinuation of MIRTAZPRIME 30 can lead to withdrawal symptoms, including nausea, anxiety, irritability, and flu-like symptoms. Therefore, any decision to stop the medication should be made in consultation with a healthcare provider who can develop an appropriate tapering schedule.\nImportant Usage Guidelines\nMIRTAZPRIME 30 should always be taken exactly as prescribed by a qualified healthcare professional. The medication is typically administered once daily, preferably in the evening before bedtime due to its sedative effects. Tablets should be swallowed whole with water and can be taken with or without food, though taking them with food may help reduce any stomach upset.\nConsistency in timing is important for maintaining stable blood levels of the medication and optimizing therapeutic effects. Patients should try to take their dose at approximately the same time each evening. If a dose is missed, it should be taken as soon as remembered unless it's close to the time for the next scheduled dose, in which case the missed dose should be skipped rather than doubling up.\nThe full therapeutic benefits of MIRTAZPRIME 30 may take several weeks to manifest. Patients should continue taking the medication as prescribed even if they don't feel immediate improvement. Premature discontinuation is a common reason for treatment failure in depression management.\nRegular follow-up appointments with the prescribing physician are essential for monitoring treatment response, adjusting dosages if necessary, and screening for potential side effects. Patients should maintain open communication with their healthcare team about their symptoms, concerns, and any changes in their condition.\nConclusion\nMIRTAZPRIME 30 represents a valuable therapeutic option in the comprehensive management of major depressive disorder and related conditions. Its unique mechanism of action, combining enhanced noradrenergic and serotonergic neurotransmission with sedative and appetite-stimulating properties, offers distinct advantages for carefully selected patients. The medication's ability to improve both mood symptoms and sleep disturbances makes it particularly useful for patients experiencing depression accompanied by insomnia.\nThe relatively favorable side effect profile, particularly regarding sexual function and gastrointestinal tolerability, enhances patient acceptance and adherence to treatment. While potential side effects such as sedation, increased appetite, and weight gain require monitoring and management, many patients find these effects tolerable compared to the debilitating symptoms of untreated depression.\nSuccess with MIRTAZPRIME 30, as with any antidepressant therapy, depends on proper patient selection, appropriate dosing, regular monitoring, and a comprehensive treatment approach that may include psychotherapy, lifestyle modifications, and social support alongside pharmacological intervention. Patients should work closely with their healthcare providers to optimize treatment outcomes and maintain long-term mental health wellness.\nThe decision to use MIRTAZPRIME 30 should always be made collaboratively between patient and physician, considering individual symptoms, treatment history, coexisting medical conditions, and personal preferences. With proper use under medical supervision, MIRTAZPRIME 30 can be an effective tool in helping patients reclaim their lives from the devastating effects of depression and move toward recovery and renewed well-being.", "price": 262.0, "discountamount": 79.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2254, "imageuri": "https://productimages.withfloats.com/actual/694d14f83d39ca31a28d046b.png", "tileimageuri": "https://productimages.withfloats.com/tile/694d14f83d39ca31a28d046b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-25T10:41:58.966Z", "updatedon": "2026-03-13T07:46:51.004Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//mirtazapine-30mg/2254", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "MIRTAZPRIME 30", "category": "NEUROLOGYRANGE", "tags": [ "MIRTAZPRIME 30", "Mirtazapine 30mg as per Indian Pharmacopoeia (IP) standards", "managing depression", "insomnia and anxiety.", "depression or anxiety.", "depredepressive episodes.", "helping patients reclaim their lives from the devastating effects of depression." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694cf85408591c1173b54c2f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Pregabalin Epalrestat and Methylcobalamin Tablets", "description": "EPSTATE ED represents an advanced pharmaceutical formulation that combines three powerful therapeutic agents: Pregabalin, Epalrestat, and Methylcobalamin. This innovative triple-combination medication is specifically designed to address the complex pathophysiology of diabetic neuropathy and neuropathic pain conditions. By integrating multiple mechanisms of action, EPSTATE ED offers a comprehensive approach to managing nerve-related complications that significantly impact the quality of life for millions of individuals worldwide.\nThe formulation addresses not only the symptomatic relief of neuropathic pain but also targets the underlying metabolic derangements that contribute to nerve damage progression. This multi-pronged therapeutic strategy makes EPSTATE ED particularly valuable for patients who require more than symptomatic management alone.\nUnderstanding the Active Components\nPregabalin: The Neuropathic Pain Modulator\nPregabalin serves as the cornerstone analgesic component in EPSTATE ED. This anticonvulsant medication works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. Through this mechanism, Pregabalin reduces the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. This reduction in neurotransmitter release effectively dampens the abnormal neural signaling that characterizes neuropathic pain conditions.\nThe molecule demonstrates excellent bioavailability and rapid absorption, allowing patients to experience relief within a relatively short timeframe. Its efficacy in managing various neuropathic pain syndromes has been extensively documented in clinical trials, establishing it as a first-line agent for diabetic peripheral neuropathy, postherpetic neuralgia, and other chronic neuropathic pain conditions.\nEpalrestat: The Aldose Reductase Inhibitor\nEpalrestat represents a unique addition to the formulation, functioning as a selective aldose reductase inhibitor. In diabetic conditions, excess glucose is converted to sorbitol through the polyol pathway, with aldose reductase serving as the rate-limiting enzyme. The accumulation of sorbitol within nerve cells leads to osmotic stress, depletion of myoinositol, and subsequent nerve dysfunction.\nBy inhibiting aldose reductase, Epalrestat prevents this harmful sorbitol accumulation, thereby addressing one of the fundamental metabolic abnormalities responsible for diabetic neuropathy. This disease-modifying approach distinguishes EPSTATE ED from purely symptomatic treatments. Epalrestat has been particularly well-studied in Asian populations and has demonstrated the ability to improve nerve conduction velocities and reduce subjective neuropathic symptoms over time.\nMethylcobalamin: The Neurotropic Vitamin\nMethylcobalamin, the bioactive form of Vitamin B12, completes the therapeutic triad in EPSTATE ED. Unlike cyanocobalamin, which requires conversion in the body, methylcobalamin is immediately available for utilization in crucial biochemical processes. It plays an indispensable role in myelin synthesis, the protective sheath surrounding nerve fibers that enables proper signal transmission.\nThis coenzyme participates in methionine synthesis and is essential for maintaining the structural and functional integrity of neurons. Methylcobalamin also facilitates nerve regeneration and has demonstrated neuroprotective properties in various experimental models. For patients with diabetic neuropathy, who often exhibit Vitamin B12 deficiency (sometimes exacerbated by metformin therapy), supplementation with methylcobalamin addresses both nutritional deficits and supports nerve health at a fundamental level.\nClinical Applications and Uses\nEPSTATE ED is primarily indicated for the comprehensive management of diabetic peripheral neuropathy, a condition affecting approximately 50% of individuals with long-standing diabetes. The symptoms of this condition range from tingling sensations and burning pain to numbness and loss of protective sensation, which can lead to serious complications including foot ulcers and amputations.\nBeyond diabetic neuropathy, EPSTATE ED may be prescribed for various neuropathic pain syndromes where the combination of pain relief, metabolic correction, and nerve support proves beneficial. Patients experiencing chronic nerve pain resulting from metabolic disturbances, nutritional deficiencies, or structural nerve damage may find this combination particularly effective.\nThe medication is typically recommended for adults who have not achieved adequate symptom control with single-agent therapy or who would benefit from the synergistic effects of the three components. Healthcare providers may prescribe EPSTATE ED when a patient requires both immediate symptom relief and long-term disease modification.\nKey Benefits and Therapeutic Advantages\nComprehensive Multi-Mechanism Action\nThe primary advantage of EPSTATE ED lies in its multi-faceted approach to neuropathic conditions. Rather than addressing only pain symptoms, the formulation simultaneously tackles pain perception, underlying metabolic abnormalities, and nutritional support for nerve health. This comprehensive strategy may lead to superior outcomes compared to monotherapy approaches.\nEnhanced Pain Relief\nClinical evidence supporting Pregabalin's efficacy in neuropathic pain is substantial. Patients often report significant reductions in pain intensity, improved sleep quality due to decreased nocturnal pain, and enhanced ability to perform daily activities. The pain-relieving effects typically manifest within the first week of therapy and continue to improve with ongoing treatment.\nDisease Modification Potential\nUnlike purely symptomatic treatments, the inclusion of Epalrestat provides genuine disease-modifying potential. By targeting the polyol pathway, EPSTATE ED may slow the progression of nerve damage in diabetic patients. Long-term use may preserve nerve function and prevent the worsening of neuropathic symptoms, offering hope beyond mere symptom management.\nImproved Nerve Conduction and Function\nThe combination of metabolic correction through Epalrestat and neurotropic support via Methylcobalamin creates an environment conducive to nerve regeneration and functional improvement. Studies have demonstrated improvements in nerve conduction velocity parameters with similar combination therapies, suggesting potential restoration of nerve function rather than simple symptom masking.\nConvenience of Combination Therapy\nFor patients who would otherwise require multiple separate medications, EPSTATE ED offers the convenience of a single tablet containing all three therapeutic agents. This simplification of medication regimens improves compliance, reduces pill burden, and may enhance overall treatment outcomes.\nQuality of Life Enhancement\nThe cumulative effect of pain reduction, improved nerve function, and better metabolic control translates into meaningful quality of life improvements. Patients report better mobility, reduced interference of pain with daily activities, improved mood, and enhanced social functioning.\nPotential Side Effects and Safety Considerations\nCommon Side Effects\nAs with any pharmaceutical agent, EPSTATE ED may produce certain adverse effects. The most commonly reported side effects are primarily attributable to the Pregabalin component and include dizziness, somnolence, peripheral edema, dry mouth, blurred vision, weight gain, and difficulty with concentration or attention. These effects are generally mild to moderate and often diminish with continued therapy as the body adapts to the medication.\nGastrointestinal symptoms such as constipation or nausea may occur, though they are typically manageable with dietary modifications or symptomatic treatment. Some patients experience increased appetite leading to weight gain, which requires monitoring, particularly in diabetic individuals where weight management is crucial.\nSerious but Rare Adverse Events\nThough uncommon, certain serious adverse effects warrant immediate medical attention. These include allergic reactions manifesting as rash, itching, swelling, severe dizziness, or breathing difficulties. Pregabalin has been associated with rare cases of angioedema, which requires prompt discontinuation and medical intervention.\nMental health changes, including mood alterations, anxiety, depression, agitation, or suicidal thoughts, have been reported with Pregabalin use, particularly in individuals with pre-existing psychiatric conditions. Patients and caregivers should remain vigilant for behavioral changes and report them immediately to healthcare providers.\nDrug Interactions and Precautions\nEPSTATE ED may interact with other central nervous system depressants, including alcohol, opioids, benzodiazepines, and antihistamines, potentially intensifying sedation and cognitive impairment. Patients should inform their healthcare provider of all medications, supplements, and substances they consume.\nIndividuals with kidney impairment require dose adjustments since Pregabalin is primarily eliminated through renal excretion. Regular monitoring of renal function may be necessary during long-term therapy.\nSpecial Population Considerations\nPregnant or breastfeeding women should use EPSTATE ED only when clearly necessary and under strict medical supervision, as the safety profile in these populations has not been fully established. Elderly patients may be more susceptible to side effects, particularly dizziness and confusion, necessitating careful dose titration and monitoring.\nPatients should be advised against abrupt discontinuation of EPSTATE ED, as sudden cessation of Pregabalin may precipitate withdrawal symptoms including insomnia, nausea, headache, anxiety, and sweating. Gradual dose reduction under medical supervision is recommended when discontinuing therapy.\nDosage and Administration Guidelines\nThe appropriate dosage of EPSTATE ED is highly individualized and should be determined by a qualified healthcare professional based on the patient's specific condition, response to therapy, and tolerance. Typically, treatment begins with a lower dose that is gradually increased to achieve optimal therapeutic benefit while minimizing adverse effects.\nPatients should take EPSTATE ED exactly as prescribed, with or without food, at consistent times each day to maintain stable blood levels. Missing doses should be addressed by taking the forgotten dose as soon as remembered, unless it's nearly time for the next scheduled dose. Double dosing to compensate for missed doses is not recommended.\nRegular follow-up appointments allow healthcare providers to assess treatment efficacy, monitor for adverse effects, and make necessary dose adjustments. Patients should maintain open communication with their medical team regarding symptom improvement, side effects, and any concerns that arise during therapy.\nPatient Counseling and Lifestyle Recommendations\nMaximizing the benefits of EPSTATE ED extends beyond simply taking the medication. Patients should be counseled on complementary lifestyle measures that support neuropathy management. Maintaining optimal glycemic control remains paramount for diabetic patients, as blood sugar management directly impacts neuropathy progression regardless of medication.\nRegular physical activity, within individual capabilities, promotes circulation, supports nerve health, and may enhance the therapeutic effects of EPSTATE ED. Daily foot examinations become critical for diabetic patients to identify potential injuries early, preventing serious complications.\nNutritional optimization, including adequate intake of B vitamins, antioxidants, and essential nutrients, supports the neurotropic effects of Methylcobalamin. Avoiding alcohol and tobacco, both of which can exacerbate neuropathy, is strongly recommended.\nPatients should be cautioned about activities requiring alertness, such as driving or operating machinery, especially during the initial treatment phase when dizziness and somnolence may be more pronounced. These effects typically improve with continued therapy, but individual responses vary.\nConclusion\nEPSTATE ED represents a thoughtfully designed pharmaceutical formulation that addresses the multifaceted nature of diabetic neuropathy and neuropathic pain through its unique combination of Pregabalin, Epalrestat, and Methylcobalamin. This triple-action approach offers patients more than symptomatic relief—it provides genuine disease modification potential, nutritional support, and comprehensive nerve health optimization.\nThe synergistic effects of these three components create a therapeutic profile that is greater than the sum of its parts. While Pregabalin efficiently manages pain symptoms and improves quality of life in the short term, Epalrestat works to address underlying metabolic derangements that drive disease progression, and Methylcobalamin provides essential neurotropic support for nerve regeneration and function.\nFor patients struggling with the debilitating effects of neuropathic pain and diabetic neuropathy, EPSTATE ED offers renewed hope for better symptom control and potentially slowed disease progression. The convenience of combination therapy in a single tablet improves adherence and simplifies complex treatment regimens.\nHowever, EPSTATE ED is not without considerations. Potential side effects, though generally manageable, require awareness and monitoring. The medication is most effective when integrated into a comprehensive management plan that includes optimal glycemic control, lifestyle modifications, and regular medical supervision.\nUltimately, EPSTATE ED should be viewed as a valuable tool in the therapeutic arsenal against neuropathic conditions, best utilized under the guidance of knowledgeable healthcare professionals who can individualize treatment to each patient's unique needs and circumstances. With proper use, monitoring, and patient education, EPSTATE ED can significantly improve outcomes and quality of life for those affected by these challenging neurological conditions.", "price": 275.0, "discountamount": 82.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2253, "imageuri": "https://productimages.withfloats.com/actual/694cf859d25fa0b0657b1ac8.png", "tileimageuri": "https://productimages.withfloats.com/tile/694cf859d25fa0b0657b1ac8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-25T08:39:48.947Z", "updatedon": "2026-04-18T09:21:49.885Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//pregabalin-epalrestat-and-methylcobalamin-tablets/2253", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "EPSTATE ED", "category": "NEUROLOGYRANGE", "tags": [ "regabalin, Epalrestat, and Methylcobalamin.neuropathic pain conditions.", "Pregabalin, Epalrestat, and Methylcobalamin.", "neuropathic pain.", "diabetic neuropathy.", "sorbitol within nerve cells leads to osmotic stress.", "Epalrestat and neurotropic support via Methylcobalamin creates an environment .", "mood alterations, anxiety, depression, agitation.", "supports the neurotropic effects of Methylcobalamin.", "Pregabalin Epalrestat and Methylcobalamin Tablets", "epalrestat and methylcobalamin tablets uses", "epalrestat and methylcobalamin tablets in hindi", "pregabalin epalrestat and methylcobalamin tablets price jaipur", "pregabalin epalrestat and methylcobalamin tablets price india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "69316145bf2a5ce08905eadf", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Temozolomide 250 mg", "description": "Temozolomide 250 mg, marketed under the brand name TMOZOLMIDE 250 by Steris Healthcare, is a potent chemotherapy drug primarily used to treat certain aggressive brain tumors such as glioblastoma multiforme (GBM) and anaplastic astrocytoma. Its mechanism of action involves alkylation of DNA, which damages the cancer cells’ DNA strands, leading to their programmed death and inhibition of tumor growth. This effect is achieved through the addition of a methyl group at the O6 and N7 positions of guanine in DNA. Tumor cells damaged by this process are unable to reproduce and eventually die, making Temozolomide an effective agent in chemotherapy regimens[,].​\n\nWhat are the benefits of temozolomide 250 mg?\nTemozolomide 250 mg offers significant benefits for patients battling brain cancers. It crosses the blood-brain barrier effectively, which allows it to reach tumor cells inside the brain where many other drugs cannot penetrate. This expands its efficacy in treating primary brain tumors and certain metastatic tumors that have spread to the brain. In clinical settings, it has been shown to improve progression-free survival rates and, in some cases, overall survival when used with radiation therapy or alone during maintenance treatment phases[,].​\n\nKey Benefits of Temozolomide 250 mg\nEffective treatment of aggressive brain tumors like glioblastoma multiforme and anaplastic astrocytoma.\n\nCan be administered orally, offering convenience compared to intravenous chemotherapy.\n\nAbility to cross the blood-brain barrier, ensuring targeted therapy within the central nervous system.\n\nWell-established as part of the standard Stupp protocol (combined with radiotherapy).\n\nMay improve quality of life by slowing tumor progression and managing symptoms associated with brain tumors[,].​\n\nSide Effects of Temozolomide 250 mg\nWhile Temozolomide is effective, it may cause side effects common to chemotherapy medications due to its impact on both cancerous and healthy rapidly dividing cells.\n\nCommon Side Effects of Temozolomide 250 mg\nNausea and vomiting, which can sometimes be severe.\n\nFatigue and weakness.\n\nHair thinning or hair loss.\n\nConstipation or diarrhea.\n\nLoss of appetite.\n\nMouth sores or changes in taste.\n\nDizziness or headache.\n\nMild skin rashes or itching[,].​\n\nSerious Side Effects of Temozolomide 250 mg\nSignificant reduction in blood cell counts causing anemia, leukopenia, or thrombocytopenia (requiring close blood monitoring).\n\nSevere infections due to immune suppression.\n\nAllergic reactions, including swelling, itching, or rash.\n\nLiver dysfunction or jaundice.\n\nSeizures or neurological symptoms.\n\nUnusual bleeding or bruising.\n\nSigns of severe allergic reaction like difficulty breathing[,].​\n\nAvailable Substitute for Temozolomide 250 mg\nThere are limited direct substitutes for Temozolomide due to its unique ability to treat brain tumors crossing the blood-brain barrier. Alternatives depend on tumor type and may include other chemotherapy drugs like lomustine (CCNU), carmustine (BCNU), or newer targeted therapies and immunotherapies under clinical trial. However, these alternatives may vary in efficacy and side effect profile and are generally used under oncologist guidance[,].\n\nDosage Guidelines for Temozolomide 250 mg\nThe dosage of Temozolomide 250 mg (TMOZOLMIDE 250) by Steris Healthcare is carefully tailored based on the type and stage of cancer, body surface area (BSA), and patient tolerance. The standard regimen for newly diagnosed glioblastoma is an oral dose of 75 mg/m² daily during radiotherapy, followed by maintenance cycles of 150 to 200 mg/m² for 5 days every 28 days. Dose adjustments are common based on blood counts and side effects. Strict adherence to the prescribed dosage schedule and monitoring are critical for safety and efficacy.", "price": 12187.0, "discountamount": 3657.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2229, "imageuri": "https://productimages.withfloats.com/actual/693161477743cf6a1359d094.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/693161477743cf6a1359d094.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-04T10:24:05.165Z", "updatedon": "2026-03-12T08:08:17.975Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//temozolomide-250-mg/2229", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TMOZOLMIDE 250", "category": "Oncology", "tags": [ "Temozolomide 250 mg", "cancer", "brain tumors", "cancer cells", "Tumor cells", "chemotherapy", "TMOZOLMIDE 250", "Temozolomide 250 mg capsule uses", "How to take Temozolomide 250 mg correctly", "Temozolomide 250 mg dosage schedule guide", "Temozolomide 250 mg dosage schedule guide", "Temozolomide 250 mg for glioblastoma treatment", "Temozolomide 250 mg empty stomach instructions", "What is Temozolomide 250 mg prescribed for", "Temozolomide 250 mg chemotherapy cycle details", "Temozolomide 250 mg patient information leaflet", "Temozolomide 250 mg storage instructions", "Temozolomide 250 mg manufacturer price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6664257c8ecffe165c356216", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Lactulose (3.33)/10ml", "description": "LACTULOOZ 200\nLactulose (3.33)/10ml\nLACTULOOZ 200 contains Lactulose at a concentration of 3.33g per 10ml. Lactulose is a synthetic sugar used as a laxative to treat constipation by increasing the water content and volume of stools, making them softer and easier to pass. It is commonly prescribed to relieve constipation in both adults and children.\n\nLactulose works by drawing water into the colon, which softens the stool and promotes regular bowel movements. It is often used to treat chronic constipation and conditions such as hepatic encephalopathy, a liver disorder that can cause confusion and other cognitive symptoms due to a buildup of toxins in the blood.\n\nThis medication is typically taken orally and may take 1 to 2 days to produce a bowel movement. It is important to follow the dosage instructions provided by your healthcare provider to achieve the desired effects without causing discomfort or side effects.\n\nCommon side effects of Lactulose may include bloating, gas, cramps, and diarrhea. These side effects are usually mild and temporary. However, if you experience severe or persistent side effects, it is important to contact your healthcare provider.\n\nLACTULOOZ 200 with Lactulose (3.33g/10ml) is an effective and commonly used laxative for the treatment of constipation and related conditions. Always consult with your healthcare provider before starting any new medication regimen.For further information:\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nORDER Now: \nhttps://www.sterisonline.com/product/lactulooz-200-133771\n\n\n\n\n\n\n", "price": 246.0, "discountamount": 74.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "3.", "33g", "gas", "10ml", "Email", "blood", "colon", "severe", "cramps", "toxins", "adults", "volume", "stools", "buildup", "children", "bloating", "laxative", "diarrhea", "WhatsApp", "Lactulose", "effective", "confusion", "LACTULOOZ", "treatment", "discomfort", "information", "1 to 2 days", "sterispharma", "sterisonline", "water content", "concentration", "liver disorder", "desired effects", "synthetic sugar", "related conditions", "dosage instructions", "healthcare provider", "Common side effects", "chronic constipation", "new medication regimen", "hepatic encephalopathy", "persistent side effects", "regular bowel movements", "other cognitive symptoms" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1566, "imageuri": "https://productimages.withfloats.com/actual/66642580470927258392989b.png", "tileimageuri": "https://productimages.withfloats.com/tile/66642580470927258392989b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-08T09:33:48.561Z", "updatedon": "2026-03-14T11:09:09.808Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//lactulose-3-33-10ml/1566", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "LACTULOOZ 200", "category": "GASTROLOGYRANGE", "tags": [ "LACTULOOZ 200", "Lactulose (3.33)/10ml", "lactulose 10 g/15 ml syrup", "lactulose 10gm/15ml solution dosage", "Lactulose syrup dose for child", "Lactulose syrup for constipation", "Best time to take lactulose" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662e74687f0960e14a2d95a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Gefitinib 250mg", "description": "\n\nGEFISTERIS 250 is a premium pharmaceutical formulation containing Gefitinib 250mg, a breakthrough targeted therapy medication manufactured by Steris Healthcare. This innovative oral medication represents a significant advancement in the treatment of non-small cell lung cancer (NSCLC), offering patients a precise, scientifically-designed approach to combating one of the world's most challenging malignancies. GEFISTERIS 250 is specifically engineered to target the underlying molecular mechanisms that drive certain types of lung cancer, providing hope and extended survival for patients who carry specific genetic mutations.\nAs a tyrosine kinase inhibitor, GEFISTERIS 250 works at the cellular level to interrupt the signals that tell cancer cells to grow and divide. This targeted approach differs fundamentally from traditional chemotherapy, which affects both healthy and cancerous cells. By focusing specifically on cancer cells with epidermal growth factor receptor (EGFR) mutations, GEFISTERIS 250 offers a more refined treatment strategy with potentially fewer systemic side effects and improved quality of life during treatment.\nUnderstanding Gefitinib 250mg: The Science Behind GEFISTERIS 250\nGefitinib 250mg, the active pharmaceutical ingredient in GEFISTERIS 250, belongs to a revolutionary class of medications known as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The development of this medication marked a paradigm shift in oncology, moving from one-size-fits-all chemotherapy approaches to personalized, mutation-specific treatments.\nThe EGFR protein is found on the surface of cells and plays a crucial role in cell growth and division. In normal cells, EGFR activation is carefully regulated. However, in certain lung cancers, mutations in the EGFR gene cause the receptor to remain constantly active, sending continuous signals for the cell to grow, divide, and survive—leading to uncontrolled cancer growth. GEFISTERIS 250 works by blocking the tyrosine kinase activity of the mutated EGFR protein, effectively turning off the growth signal and causing cancer cells to stop proliferating and eventually die.\nThis precision targeting is what makes GEFISTERIS 250 particularly effective for patients whose tumors harbor activating EGFR mutations, particularly the common exon 19 deletions or exon 21 L858R substitution mutations. Before initiating treatment with GEFISTERIS 250, patients undergo molecular testing to confirm the presence of these mutations, ensuring that the therapy is appropriately matched to their specific cancer biology.\nPrimary Uses and Indications of GEFISTERIS 250\nGEFISTERIS 250 is primarily indicated for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors have specific EGFR mutations. The medication is approved for both first-line treatment in newly diagnosed patients and for those whose disease has progressed after platinum-based chemotherapy.\nFirst-Line Treatment: When EGFR mutations are detected in treatment-naïve patients, GEFISTERIS 250 offers an excellent first-line option, often providing superior progression-free survival compared to traditional chemotherapy regimens. Patients starting with targeted therapy typically experience better tolerability and quality of life during initial treatment phases.\nSecond-Line and Beyond: For patients whose cancer has progressed after chemotherapy, GEFISTERIS 250 provides an effective alternative treatment option, particularly when EGFR mutation testing was not performed initially or when the mutation status was unknown at the time of first treatment.\nThe medication is taken orally as a once-daily tablet, offering significant convenience compared to intravenous chemotherapy that requires hospital visits and lengthy infusion times. This oral administration allows patients to maintain greater independence and normalcy in their daily lives while receiving effective cancer treatment.\nKey Benefits of GEFISTERIS 250\n1. Targeted Cancer Fighting Action\nThe primary benefit of GEFISTERIS 250 lies in its precision targeting mechanism. Unlike conventional chemotherapy that attacks all rapidly dividing cells in the body, GEFISTERIS 250 specifically targets cancer cells bearing EGFR mutations. This selective action means that healthy cells are largely spared, resulting in a more favorable side effect profile and better preservation of normal bodily functions during treatment.\n2. Superior Efficacy in EGFR-Mutant NSCLC\nClinical trials have consistently demonstrated that GEFISTERIS 250 and other EGFR-TKIs provide superior progression-free survival compared to chemotherapy in patients with EGFR-mutant NSCLC. Response rates typically range from 60-80% in appropriate patient populations, with many patients experiencing significant tumor shrinkage and symptomatic improvement within weeks of starting treatment.\n3. Improved Quality of Life\nPatients taking GEFISTERIS 250 often report better quality of life compared to those receiving traditional chemotherapy. The medication's targeted nature results in fewer debilitating side effects such as severe nausea, hair loss, and profound fatigue. Many patients can continue working, traveling, and engaging in normal daily activities while on treatment.\n4. Convenient Oral Administration\nGEFISTERIS 250's once-daily oral dosing eliminates the need for frequent hospital visits for intravenous chemotherapy infusions. Patients take one tablet daily at home, providing tremendous convenience and reducing the burden of treatment. This ease of administration contributes significantly to treatment adherence and patient satisfaction.\n5. Rapid Symptom Relief\nMany patients experience rapid improvement in cancer-related symptoms such as cough, shortness of breath, chest pain, and fatigue within the first few weeks of GEFISTERIS 250 treatment. This quick symptomatic relief can dramatically improve quality of life even before significant tumor shrinkage is visible on imaging studies.\n6. Extended Survival Benefits\nLong-term data demonstrates that appropriate use of EGFR-TKIs like GEFISTERIS 250 contributes to extended overall survival in patients with EGFR-mutant lung cancer. When used as part of a comprehensive treatment strategy, including potential sequential therapies after progression, patients can achieve survival times that were unimaginable before the advent of targeted therapies.\n7. Manageable Side Effect Profile\nWhile GEFISTERIS 250 does cause side effects, they are generally more manageable than those associated with traditional chemotherapy. Most side effects can be effectively controlled with supportive medications, dose modifications, or temporary treatment interruptions, allowing patients to continue benefiting from therapy.\n8. Quality Manufacturing by Steris Healthcare\nGEFISTERIS 250 benefits from Steris Healthcare's commitment to pharmaceutical excellence. Each tablet undergoes rigorous quality testing to ensure consistent potency, purity, and bioavailability. This quality assurance means patients receive reliable, effective medication with every dose.\nSide Effects of GEFISTERIS 250 (Gefitinib 250mg)\nWhile GEFISTERIS 250 offers significant therapeutic benefits, patients should be aware of potential side effects. Understanding these effects enables early recognition and appropriate management.\nCommon Side Effects (Affecting 20% or More of Patients):\nSkin Reactions: The most characteristic side effect of GEFISTERIS 250 is an acne-like rash, typically appearing on the face, chest, and back within the first few weeks of treatment. This rash, while cosmetically concerning for some patients, actually correlates with better treatment response. The rash can be managed with topical antibiotics, moisturizers, and sun protection. In severe cases, temporary dose reduction may be necessary.\nDiarrhea: Approximately 50-60% of patients experience diarrhea of varying severity. Mild diarrhea can often be managed with dietary modifications and over-the-counter anti-diarrheal medications like loperamide. Patients should stay well-hydrated and contact their healthcare provider if diarrhea becomes severe or persistent, as dose adjustments may be needed.\nNail Changes: Some patients develop paronychia (nail bed inflammation) or other nail abnormalities. Proper nail care, avoiding trauma to the nail beds, and wearing protective gloves during housework can help minimize these effects.\nDry Skin: Many patients experience skin dryness and itching. Regular use of fragrance-free moisturizers, gentle cleansers, and avoidance of hot showers can help manage these symptoms.\nMouth Sores: Oral mucositis or stomatitis can develop in some patients. Good oral hygiene, avoiding spicy or acidic foods, and using alcohol-free mouthwashes can provide relief.\nLess Common but Serious Side Effects:\nInterstitial Lung Disease (ILD): While rare (1-2% of patients), ILD is the most serious potential side effect of GEFISTERIS 250. Symptoms include sudden onset or worsening of respiratory symptoms such as difficulty breathing, cough, or fever. This requires immediate medical attention and usually necessitates permanent discontinuation of the medication.\nLiver Function Abnormalities: Elevated liver enzymes can occur, requiring regular monitoring through blood tests. Most cases are asymptomatic and reversible with dose modification or temporary discontinuation.\nEye Problems: Dry eyes, corneal erosion, or other ocular issues may develop. Regular use of lubricating eye drops and ophthalmological evaluation when symptoms occur can prevent serious complications.\nGastrointestinal Perforation: Though rare, serious gastrointestinal complications including perforation can occur, particularly in patients with underlying GI conditions.\nManagement Strategies:\nMost side effects can be effectively managed through:\n\nProactive supportive care and prophylactic measures\nDose modifications (reduction to 250mg every other day in some cases)\nTemporary treatment interruptions allowing recovery\nSymptomatic treatment with appropriate medications\nPatient education about early recognition and reporting of symptoms\n\nPatients should maintain open communication with their healthcare team, reporting any new or worsening symptoms promptly. Regular monitoring through clinical visits and laboratory testing helps identify and address side effects before they become serious.\nDosage and Administration Guidelines\nThe standard dose of GEFISTERIS 250 is one 250mg tablet taken orally once daily, with or without food. The tablet should be swallowed whole with water and should not be crushed or chewed. If a dose is missed and it's been less than 12 hours since the scheduled time, patients should take the missed dose. If more than 12 hours have passed, skip the missed dose and resume the regular schedule—never double up on doses.\nTreatment continues until disease progression or unacceptable toxicity occurs. Some patients remain on GEFISTERIS 250 for months or even years if they continue to benefit without prohibitive side effects. Dose modifications may be necessary based on individual tolerance, typically reducing the frequency to every other day rather than lowering the individual dose.\nPrecautions and Important Considerations\nPatients taking GEFISTERIS 250 should be aware of several important precautions. The medication can cause harm to developing fetuses, so women of childbearing potential must use effective contraception during treatment and for at least two weeks after the last dose. Breastfeeding should be avoided during treatment and for two weeks after completion.\nGEFISTERIS 250 can interact with medications that affect stomach acid, including proton pump inhibitors and H2-receptor antagonists. If antacids are needed, they should be taken several hours apart from GEFISTERIS 250. The medication may also interact with certain other drugs metabolized by the liver, so patients should inform their healthcare provider about all medications, supplements, and herbal products they're taking.\nRegular monitoring is essential during GEFISTERIS 250 treatment, including periodic liver function tests, pulmonary symptom assessment, and clinical evaluation for skin and other toxicities. Patients should avoid prolonged sun exposure and use high-SPF sunscreen, as the medication can increase photosensitivity.\nConclusion\nGEFISTERIS 250 represents a transformative treatment option for patients with EGFR-mutant non-small cell lung cancer, offering targeted, effective therapy with a manageable side effect profile. Manufactured by Steris Healthcare with unwavering commitment to quality and patient outcomes, GEFISTERIS 250 delivers Gefitinib 250mg in a formulation designed for optimal bioavailability and consistent therapeutic effect.\nThe medication's precision targeting of cancer-driving mutations, combined with convenient oral administration and generally tolerable side effects, makes GEFISTERIS 250 an excellent choice for eligible patients. While side effects do occur and require monitoring and management, the potential benefits—including tumor response, symptom improvement, extended progression-free survival, and enhanced quality of life—often significantly outweigh the risks for appropriately selected patients.\nSuccess with GEFISTERIS 250 requires partnership between patients and their healthcare teams. Molecular testing to confirm EGFR mutation status before treatment, adherence to the prescribed regimen, proactive management of side effects, and regular monitoring all contribute to optimal outcomes. For many patients with EGFR-mutant lung cancer, GEFISTERIS 250 offers not just treatment, but genuine hope for extended, quality life.\nAs personalized medicine continues to evolve, medications like GEFISTERIS 250 exemplify the power of matching treatments to individual tumor characteristics. Steris Healthcare's commitment to delivering this advanced therapy with assured quality and accessibility ensures that more patients can benefit from the remarkable advances in targeted cancer treatment that Gefitinib 250mg represents.\n", "price": 2760.0, "discountamount": 828.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "food", "Call", "Uses", "Rash", "Note", "NSCLC", "Email", "nausea", "Dosage", "spread", "WhatsApp", "diarrhea", "Gefitinib", "treatment", "One tablet", "GEFISTERIS", "information", "sterispharma", "consultation", "sterisonline", "Side Effects", "cancer cells", "targeted therapy", "Regular monitoring", "healthcare provider", "small cell lung cancer", "healthcare professional", "specific EGFR mutations", "epidermal growth factor receptor", "potential liver function alterations" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1530, "imageuri": "https://productimages.withfloats.com/actual/667d25ffb56721898510e93e.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d25ffb56721898510e93e.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T10:56:06.808Z", "updatedon": "2026-04-15T10:04:00.767Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//gefitinib-250mg/1530", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GEFISTERIS 250", "category": "Oncology", "tags": [ "gefitinib 250 mg uses", "gefitinib 250 mg online purchase", "gefitinib 250 mg tablets price in india", "non-small cell lung cancer (NSCLC).", "triggered by chemotherapy.", "cancer biology.", "Superior Efficacy in EGFR-Mutant NSCLC", "gefitinib 250mg", "gefitinib 250mg tablet", "gefitinib 250mg tab", "gefitinib 250 mg tablet uses in lung cancer", "gefitinib tablets 250 mg dosage and benefits", "gefitinib 250 mg price in india", "gefitinib 250 mg EGFR inhibitor for NSCLC treatment india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6661a73687f0960e14a2c739", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "mycophenolate sodium 360 mg", "description": "MYCOPLASM S 360 \nMycophenolate sodium 360 mg is an essential immunosuppressant medication designed to prevent organ transplant rejection, particularly for kidney, heart, and liver transplants. As the sodium salt of mycophenolic acid, it delivers 360 mg of the active moiety per tablet, providing targeted immune suppression to help patients maintain their new organs long-term. This product stands out for its enteric-coated formulation, which enhances gastrointestinal tolerability compared to other forms, making it a preferred choice in post-transplant care regimens.​\n\nUses of Mycophenolate Sodium 360 mg\nMycophenolate sodium 360 mg primarily serves as a prophylactic agent against acute rejection in adult and pediatric patients receiving allogeneic renal, cardiac, or hepatic transplants. It works alongside other immunosuppressants like cyclosporine and corticosteroids to create a balanced regimen that minimizes the risk of graft loss. Clinically, it proves effective in de novo transplant recipients, where starting therapy early post-surgery significantly reduces rejection episodes. Beyond transplants, off-label applications include managing refractory autoimmune conditions such as lupus nephritis or myasthenia gravis, where immune overactivity damages tissues.​\n\nThe drug targets the proliferation of T- and B-lymphocytes, key players in immune responses that can attack transplanted organs. In renal transplant patients, for instance, it helps preserve kidney function by curbing antibody-mediated rejection. Its role extends to maintenance therapy, where consistent dosing sustains immunosuppression without excessive toxicity. Healthcare providers often adjust it based on patient response and trough levels of the active metabolite, mycophenolic acid (MPA), ensuring optimal therapeutic outcomes.​\n\nKey Benefits of Mycophenolate Sodium 360 mg\nMycophenolate sodium 360 mg offers several advantages that make it a cornerstone in transplant medicine. One primary benefit is its selective inhibition of lymphocyte proliferation, sparing other cell types and reducing broad-spectrum immunosuppression risks. This leads to fewer opportunistic infections compared to older agents like azathioprine. The enteric coating minimizes upper GI upset, improving patient compliance—studies show higher adherence rates with this formulation.​\n\nEnhanced Graft Survival: Prolongs organ viability by effectively suppressing cell-mediated and humoral immunity, with clinical data showing reduced biopsy-proven rejection rates.\n\nImproved Tolerability: Lower incidence of nausea and diarrhea due to delayed-release technology, allowing twice-daily dosing without food restrictions.\n\nFlexible Dosing: Equivalent to 720 mg mycophenolate mofetil, but with predictable MPA exposure via enterohepatic recirculation for steady-state efficacy.\n\nPediatric Suitability: Approved for children over 2 years in renal transplants, supporting growth without compromising safety.\n\nCost-Effective Long-Term Option: Balances efficacy and side effect profile, potentially lowering overall healthcare costs from fewer rejections or hospitalizations.​\n\nPatients experience better quality of life, with sustained energy levels and fewer interruptions from acute rejection crises. Its metabolism to MPA via liver glucuronidation ensures reliable pharmacokinetics, even in patients with mild renal impairment.​\n\nSide Effects of Mycophenolate Sodium 360 mg\nWhile highly effective, mycophenolate sodium 360 mg carries risks typical of immunosuppressants, necessitating vigilant monitoring. Common adverse effects stem from its impact on rapidly dividing cells, particularly in the gut and bone marrow.\n\nCommon Side Effects\nGastrointestinal issues like diarrhea, nausea, vomiting, and abdominal pain, affecting up to 30-50% of users.\n\nHeadache, insomnia, and tremor, often mild and transient.\n\nInfections such as urinary tract or respiratory, due to moderated immunity.\n\nHypertension or peripheral edema, manageable with supportive care.\n\nLeukopenia or anemia, requiring periodic blood counts.​\n\nSerious Side Effects\nSevere myelosuppression leading to neutropenia or thrombocytopenia, which can increase infection or bleeding risks.\n\nProgressive multifocal leukoencephalopathy (PML), a rare brain infection linked to JC virus reactivation.\n\nGastrointestinal perforation or bleeding, especially in at-risk patients.\n\nIncreased malignancy risk, including lymphoma or skin cancers, over long-term use.\n\nHypersensitivity reactions like rash or anaphylaxis.​\n\nRegular complete blood counts, viral monitoring (e.g., CMV, BK virus), and skin exams mitigate these risks. Dose reductions or discontinuation may be needed if counts drop significantly.​\n\nMechanism of Action\nMycophenolate sodium 360 mg rapidly hydrolyzes to mycophenolic acid (MPA), a potent, reversible, non-competitive inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH). This enzyme catalyzes the rate-limiting step in de novo guanine nucleotide synthesis, depleting guanosine nucleotides essential for T- and B-cell DNA replication. Lymphocytes, reliant on this pathway, undergo proliferation arrest, suppressing both cell-mediated immunity and antibody production.​\n\nMPA also hinders glycosylation of adhesion molecules on lymphocytes and monocytes, impeding their migration to graft sites. It reduces nitric oxide production in macrophages without affecting endothelial cells, curbing inflammation. Enterohepatic recirculation of the glucuronide metabolite (MPAG) prolongs MPA exposure, enhancing efficacy. Protein binding to albumin (around 97%) ensures targeted delivery, with clearance primarily renal for the inactive form.​\n\nDosage and Administration Guidelines\nStandard dosing for renal transplant is 720 mg (two 360 mg tablets) twice daily, starting within 72 hours post-surgery. Adjustments occur for hepatic or cardiac transplants, often alongside cyclosporine. Therapeutic drug monitoring of MPA AUC (area under curve) optimizes levels between 30-60 mcg·h/mL. Take on an empty stomach for best absorption, though food has minimal impact due to the coating.​\n\nPrecautions and Warnings\nAvoid in pregnancy (Category D) due to teratogenicity—use contraception and regular pregnancy tests. Contraindicated in active untreated infections. Monitor for GI bleeding in ulcerative colitis patients. Drug interactions with antacids, cholestyramine, or rifampin alter MPA levels. Live vaccines are prohibited.​\n\nConclusion\nMycophenolate sodium 360 mg represents a vital advancement in transplant immunosuppression, offering robust protection against rejection with a favorable benefit-risk profile. Its targeted action on lymphocytes, combined with improved GI tolerance, empowers patients to thrive post-transplant. By integrating it into comprehensive regimens with close monitoring, healthcare teams maximize graft success and patient well-being. Always consult a specialist for personalized guidance to harness its full potential safely.\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nORDER Now: \nhttps://www.sterisonline.com/product/mycoplasm-s-360-133670\n\n\n\n\n\n\n", "price": 767.0, "discountamount": 567.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "dose", "risk", "body", "part", "ORDER", "360mg", "Email", "cells", "dosage", "nausea", "vomiting", "schedule", "headache", "strength", "WhatsApp", "diarrhea", "activity", "rejection", "treatment", "infections", "supplements", "information", "MYCOPLASM S", "sterispharma", "sterisonline", "stomach pain", "blood counts", "immune system", "complications", "liver problems", "liver function", "other medications", "Regular monitoring", "medical conditions", "healthcare provider", "Common side effects", "Serious side effects", "white blood cell count", "potential drug interactions", "optimal therapeutic effects", "combination therapy regimen", "organ transplant recipients", "Mycophenolate Sodium therapy", "other immunosuppressive drugs" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1474, "imageuri": "https://productimages.withfloats.com/actual/6661a739c749b7962dbc08c6.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/6661a739c749b7962dbc08c6.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:10:30.488Z", "updatedon": "2026-03-12T08:02:36.733Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//mycophenolate-sodium-360-mg/1474", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "MYCOPLASM S 360 ", "category": "Oncology", "tags": [ "MYCOPLASM S 360", "Mycophenolate sodium (360mg)", "Mycophenolate sodium 360 mg price", "Mycophenolate sodium 360 mg brands", "Mycophenolate sodium 360 mg side effects", "Myfortic 360 alternative", "Myfortic 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }